Affirms U.S. LINZESS Net Sales view of $800M – $850M. High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharma: Hold Rating Maintained Amid Revenue Uncertainty and Long-term Concerns
- IRWD Earnings this Week: How Will it Perform?
- Ironwood backs FY25 revenue view $260M-$290M, consensus $287.07M
- Ironwood downgraded to Hold from Buy at Craig-Hallum
- Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide’s Phase 3 Trial and Strategic Options
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue